Overview
Raptor Pharmaceuticals Corp. focuses on improving drug targeting to expand the reach and benefit of existing therapeutics into underserved patient populations.
UCSD Recruiting Cystinosis Patients
UCSD is recruiting cystinosis patients for first clinical trial of Raptor’s Cysteamine Bitartrate Delayed-release Capsules. Raptor's DR Cysteamine is an investigational, delayed-release (DR) oral formulation of cysteamine bitartrate for the potential treatment of nephropathic cystinosis (cystinosis), a rare lysosomal storage disease.
